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ABSTRACT
Objectives To compare the clinical effectiveness of (1) 
physiotherapist- led exercise versus an exercise leaflet, 
and (2) ultrasound- guided subacromial corticosteroid 
injection versus unguided injection for pain and function 
in subacromial pain (formerly impingement) syndrome 
(SAPS).
Methods This was a single- blind 2×2 factorial 
randomised trial. Adults with SAPS were randomised 
equally to one of four treatment groups: (1) ultrasound- 
guided corticosteroid injection and physiotherapist- led 
exercise, (2) ultrasound- guided corticosteroid injection 
and an exercise leaflet, (3) unguided corticosteroid 
injection and physiotherapist- led exercise and (4) 
unguided corticosteroid injection and an exercise 
leaflet. The primary outcome was the Shoulder Pain and 
Disability Index (SPADI), collected at 6 weeks, 6 and 
12 months and compared at 6 weeks for the injection 
interventions and 6 months for the exercise interventions 
by intention to treat.
Results We recruited 256 participants (64 treatment 
per group). Response rates for the primary outcome 
were 94% at 6 weeks, 88% at 6 months and 80% at 
12 months. Greater improvement in total SPADI score 
was seen with physiotherapist- led exercise than with the 
exercise leaflet at 6 months (adjusted mean difference 
−8.23; 95% CI −14.14 to -2.32). There were no 
significant differences between the injection groups at 6 
weeks (−2.04; −7.29 to 3.22), 6 months (−2.36; −8.16 
to 3.44) or 12 months (1.59; −5.54 to 8.72).
Conclusions In patients with SAPS, physiotherapist- 
led exercise leads to greater improvements in pain 
and function than an exercise leaflet. Ultrasound 
guidance confers no additional benefit over unguided 
corticosteroid injection.
Trial registration number ISRCTN42399123.
INTRODUCTION
Shoulder pain is an important cause of disability, 
affecting one in five adults.1 2 Half of cases are 
due to subacromial pain (formerly impingement) 
syndrome (SAPS).2 Treatment guidelines recom-
mend non- surgical management as the mainstay 
including education/self- management advice, exer-
cise, corticosteroid injection and analgesia.3 4
Exercise is thought to reduce SAPS- related 
pain and disability by addressing posture, muscle 
(including rotator cuff) weakness, scapular stability 
and impaired scapulohumeral rhythm, but trials 
are often small, of poor methodological quality 
and include only short- term follow- up.5–9 Super-
vised, progressed shoulder exercises are effective 
in the short term but the optimum type, intensity 
and duration are unknown.3 6–8 10–12 A system-
atic review of contextual factors associated with 
outcome concluded that physiotherapists should 
be involved in the design and delivery of exercise 
programme for SAPS.11 SAPS is commonly treated 
with corticosteroid injections although their effi-
cacy is debated.13–15 Poor response to injection 
has been attributed to inaccurate placement of the 
injection,16 among other factors. Ultrasound guid-
ance might improve accuracy, but small randomised 
trials have not consistently confirmed the superi-
ority of ultrasound- guided injection over unguided 
injection in patients with SAPS.17–21
The SUbacromial imPingement syndrome and 
Pain: a randomised controlled trial Of exeRcise 
and injecTion trial aimed to assess whether greater 
improvements in pain and function were obtained 
with (1) a physiotherapist led, individualised, super-
vised and progressed exercise programme versus a 
standardised advice and exercise leaflet, and (2) 
ultrasound- guided subacromial corticosteroid injec-
tion versus unguided injection.
METHODS
Study design
This was a pragmatic 2×2 factorial single- blind 
randomised trial conducted within the National 
Health Service (NHS). The trial protocol has been 
published previously.22 The economic evaluation 
conducted alongside the trial will be published 
separately.
Participants
Participants were referred by their general prac-
titioner (GP) to one of two NHS community 
musculoskeletal services in Staffordshire, England. 
Following clinician review of their GP's referral 
letter, consecutive shoulder pain patients were 
mailed a participant information sheet prior to a 
clinical appointment where eligibility was assessed 
by rheumatologists, rehabilitation medicine special-
ists, extended scope physiotherapists or GPs with 
a special musculoskeletal interest. Participants were 
aged ≥18 years, had no significant shoulder trauma 
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and had a clinical diagnosis of SAPS (pain in the deltoid inser-
tion area, positive Neer or Hawkins- Kennedy tests, and pain on 
shoulder abduction as was widely accepted at trial commence-
ment).22 23 Exclusion criteria were (1) the main complaint 
being due to neck problems, acromioclavicular pathology, 
other shoulder disorders, inflammatory arthritis, polymyalgia 
rheumatica or malignancy; (2) previous (or awaited) ipsilat-
eral shoulder surgery; (3) coagulopathy, warfarin therapy; (4) 
shoulder injection or shoulder- focused exercise programme 
in the preceding month and (5) inability to provide informed 
consent, complete written questionnaires or read documentation 
written in English. Written informed consent to participate was 
obtained by a research nurse.
Randomisation and masking
Participants were randomly allocated in a 1:1:1:1 ratio to one 
of four treatment groups using stratified block randomisation 
(stratified by clinic):
1. Ultrasound- guided subacromial corticosteroid injection 
and physiotherapist- led individualised, supervised and pro-
gressed exercise.
2. Ultrasound- guided subacromial corticosteroid injection and 
an advice and exercise leaflet.
3. Unguided subacromial corticosteroid injection and 
physiotherapist- led individualised, supervised and pro-
gressed exercise.
4. Unguided subacromial corticosteroid injection and advice 
and exercise leaflet.
A trial administrator in the clinic arranged randomisa-
tion through Keele University Clinical Trial Unit’s telephone 
randomisation service. Participants and clinicians were aware 
of treatment allocation. The research nurse remained blind to 
allocation. Participants’ GPs were informed by letter of their 
patient’s participation.
Interventions
Physiotherapist-led individualised, supervised and progressed 
exercise
The protocol for the physiotherapist- led exercise programme 
can be found at: https://www. keele. ac. uk/ media/ keeleuniversity/ 
ri/ primarycare/ docs/ SUPPORT_ Physiotherapy_ Intervention_ 
Manual_ v3. 0_ 04_ 01_ 11_ Internet_ Version. pdf. The exercise 
programme was delivered by 20 community- based, musculoskel-
etal physiotherapists who completed a 2- day training workshop 
about the exercise treatment protocol. It commenced within 3 
weeks of recruitment and injection. Exercise type and dose were 
individualised, supervised and progressed in 6–8 sessions over a 
period of 12–16 weeks. Exercises were progressed through three 
stages guided by an individualised written exercise sheet and 
a computerised package,24 aiming to support the patient back 
to their specific everyday physical, sporting and occupational 
activities25:
1. Scapular stability exercise and active movement without 
resistance.
2. Range of movement exercises, isometrics and stretches, with 
scapular control in pain- free range.
3. Through- range resistance exercises, progressed to encour-
age rotator cuff muscle strengthening through all ranges of 
movement.
Treatment approaches included patient self- monitoring, goal 
setting and a written individualised home exercise programme. 
Non- attenders were offered up to two further appointments.
Advice and exercise leaflet
The leaflet was provided following corticosteroid injection and 
included information about shoulder anatomy and SAPS; simple 
self- help messages about analgesia, cold packs and activities; 
and six standardised specific strengthening and range of motion 
exercises to be performed 2–3 times daily, with no instructions 
for individualisation or progression.3
Ultrasound-guided subacromial corticosteroid injection
Ultrasound- guided injections were performed by one of nine 
clinicians using the LOGIQ e system with a 12 MHz transducer.22 
Clinicians either had extensive clinical experience performing 
ultrasound- guided injections or completed an accredited course 
on ultrasound- guided subacromial injections; all attended a 
half- day injection protocol workshop and passed a clinical 
competency test by a consultant musculoskeletal sonographer 
(AH). The skin and transducer were cleaned with chlorhexi-
dine 0.5% solution and sterile gel applied to the transducer. The 
participant sat with the shoulder internally rotated and the ipsi-
lateral hand on the buttock to maximise visibility of and access 
to the subacromial bursa. The transducer was placed anterolat-
erally, the hypoechoic subacromial bursa visualised, and a 21 G 
needle inserted under real- time ultrasound guidance until the 
needle- tip entered the bursa. A commercially available premixed 
solution of methylprednisolone 40 mg and 1 mL 1% lidocaine 
was injected into the bursa.
Unguided subacromial corticosteroid injection
Unguided subacromial injections were performed by one of 
eight clinicians, different to those performing ultrasound- 
guided injections. Clinicians had extensive clinical experience 
performing subacromial injections, and attended a half- day 
injection protocol workshop. The participant sat with their arm 
hanging with the elbow bent and forearm resting on their lap. 
The skin was cleaned with chlorhexidine solution 0.5%. A 21 
G needle was inserted through the deltoid under the acromion 
process laterally. The same premixed solution of methylprednis-
olone 40 mg and 1 mL 1% lidocaine was injected.
Following ultrasound- guided or unguided injection, participants 
were advised not to drive immediately after injection and to avoid 
pushing/pulling movements with the affected arm and heavy/repet-
itive tasks for 2 weeks. A second injection as per treatment alloca-
tion was permitted at the treating clinician’s discretion.
Data collection
Baseline data were collected by self- complete questionnaire imme-
diately before randomisation. Participants were contacted by a 
blinded research nurse 1- week postrandomisation by text message 
or telephone (according to patient preference) to assess presence 
and intensity of shoulder pain (0–10 Numeric Rating Scale (NRS)). 
All outcome measures were collected at 6 weeks, 6 months and 12 
months postrandomisation by postal self- complete questionnaire 
(adverse events were collected at 6 weeks only). Postal reminders 
were sent to non- responders 2 and 4 weeks after mailing. Non- 
responders to the reminders were telephoned by the blinded 
research nurse to collect the primary outcome measure. Partici-
pants unsuccessfully contacted after five telephone attempts were 
mailed a brief minimum data questionnaire.
Outcomes
The primary outcome was the Shoulder Pain and Disability 
Index (SPADI) total score.26 Secondary outcomes included 
the SPADI pain and function subscores, current shoulder pain 
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intensity (0–10 NRS), shoulder pain at night,27 patient’s self- 
reported global impression of change,28 Short Form-12,29 pain 
self- efficacy,30 fear avoidance,31 work (time off, performance, 
presenteeism),32 further corticosteroid injections, treatment 
preferences and expectations, illness perceptions,33 exercise 
adherence (agreement exercises performed as advised, number of 
times performed, duration) and treatment satisfaction. Adverse 
events were collected using clinical case report forms, partici-
pant self- report, primary care physician report and the 6 weeks 
follow- up questionnaire.
Statistical analysis
Sample size
We aimed to detect a small- moderate effect size (standardised 
mean difference 0.4), equating to an approximately 8- point 
difference (SD 20) in the SPADI total score for the two main 
effects (ultrasound- guided vs unguided injection; physiothera-
pist- led exercise vs leaflet).34 35 The primary end point was 6 
months for the exercise interventions and 6 weeks for the injec-
tion comparisons, since corticosteroid injection improves pain 
and function more rapidly than exercise.28 36 A sample size of 
Figure 1 Flow of participants. *6 patients did not attend physiotherapy sessions, one of them also received unguided instead of US- guided 
injection; †5 patients did not attend physiotherapy sessions, two of them also did not receive unguided injection; ‡1 patient did not receive unguided 
injection. Reasons for cumulative withdrawal: (a) at 6 weeks– in group 1, time commitments (1), difficulty in completing questionnaires (1), in group 
3, relocation (1); (b) at 6 months– in group1, not happy with study arm allocated (1); group 2– exercise did not work (1), relocation (1); group 3- did 
not want to continue with trial (2); group 4–did not want to continue with the trial (3); (c) at 12 months– in group1, did not want to continue with the 
trial (1), could not continue completing questionnaires due to frozen shoulders (1), and an operation (1); in group 2–did not want to continue with the 
trial (2), listed for shoulder surgery (1); in group 3–not happy with the study group allocated (1); in group 4–listed for surgery (1) and not happy with 
the arm allocated (1). SIS, subacromial impingement syndrome; US, ultrasound.
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250 participants was needed (80% power; 5% two- tailed signif-
icance; 20% lost to follow- up).
Analysis
The primary analysis was by intention to treat (ITT) and double- 
analysed independently by two statisticians, blinded to treatment 
allocation until the per- protocol analysis. Descriptive statistics 
(mean (SD) or frequency counts (percentages)) summarised 
participants’ baseline characteristics by treatment group. We 
estimated treatment effects using mixed- effect models (linear 
for numerical outcomes and logistic for dichotomous outcomes) 
unadjusted and then adjusting for age, gender, baseline SPADI 
score, pain duration and clinic location. The primary between- 
group evaluations were the mean differences (adjusted) in total 
SPADI score at 6 weeks between those randomised to receive 
ultrasound- guided versus unguided injection and at 6 months 
between those randomised to physiotherapist- led exercise versus 
the leaflet. The longitudinal mixed models upheld the full ITT 
through the inclusion of all randomised participants utilising all 
available data. Under the missing at random (MAR) assumption 
(ie, conditional on the observed data such as outcome data at 
other time points and key baseline covariates, the missingness 
is independent of the unobserved measurement), the model 
uses likelihood- based estimation methods to produce unbiased 
parameter estimates and standard errors. MAR is more plausible 
than the missing completely at random assumption on which 
complete case analysis is based.
Secondary analyses included between- group comparisons of 
the SPADI subscales and other outcome measures at 6 weeks, 
6 months and 12 months, and current shoulder pain intensity 
at week 1. Primary interest focused on main effects (‘at the 
margins’) evaluation as the two interventions were assumed to 
act independently of each other. We estimated the interaction 
effect from a separate regression model (by including an inter-
action term). A per- protocol sensitivity analysis excluded partic-
ipants who did not receive the randomly allocated injection or 
those in the physiotherapist- led exercise group who did not 
attend 6–8 treatment sessions.22 A post hoc complier- average- 
causal effect (CACE) analysis was also undertaken to measure 
the unbiased impact of the two interventions across complier 
subgroups. CACE analysis requires the following assumptions: 
(1) potential outcomes for each participant are independent of 
the outcomes for other participants; (2) there is a monotonic 
relationship between treatment assignment and receipt, that 
is, there are no individuals for whom assignment to treatment 
reduces the likelihood of receiving treatment (ie, no defiers); 
(3) the proportion of compliers taking the active treatment is 
nonzero; (4) assignment to treatment is random and the propor-
tion of compliers is, on average, the same across intervention 
and control groups; and (5) exclusion restriction, that is, treat-
ment assignment is independent of the potential outcome given 
the treatment received. Analyses were performed using Stata 
V.13 (StataCorp).
Patient and public involvement
The idea for this trial was developed in collaboration with 
research users with SAPS who provided feedback on the 
proposed recruitment and consent processes and choice of trial 
outcomes. Two patient representatives sat on the independent 
trial steering committee and provided feedback and advice on 
the design of questionnaires and participant information leaf-
lets. They also played a full part in monitoring the progress and 
conduct of the trial.
RESULTS
Between 31 May 2011 and 29 November 2012, 1421 partic-
ipants were mailed trial information: 1275 were assessed, of 
whom 474 were eligible (figure 1). A total of 256 eligible partic-
ipants gave informed consent and were randomised, 64 per 
group. Demographic characteristics were similar between partic-
ipants (n=256) and non- participants (n=218): mean (SD) age 
53.8 (10.2) vs 55.4 (15.0); 52.0% vs 51.4% female. Participants’ 
baseline characteristics are shown in table 1. Twelve participants 
did not receive the allocated intervention and 20 withdrew 
during follow- up (figure 1). Primary outcome responses were 
94% at 6 weeks, 88% at 6 months and 80% at 12 months.
Greater improvement in the total SPADI score was seen with 
physiotherapist- led exercise than the leaflet at 6 months: 6 weeks 
−1.60 (95% CI −6.99 to 3.80), 6 months −8.23 (−14.14 to 
–2.32) and 12 months −4.25 (−11.48 to 2.99) (figure 2). There 
were no significant between- group differences for the two injec-
tion groups: 6 weeks −2.04 (95% CI −7.29 to 3.22), 6 months 
−2.36 (−8.16 to 3.44) and 12 months 1.59 (−5.54 to 8.72).
There were greater improvements in SPADI pain and disability 
subscales with physiotherapist- led exercise than the leaflet at 
6 months but not at 6 weeks and 12 months (table 2). Fewer 
people in the physiotherapist- led exercise group than the leaflet 
group reported shoulder pain at night at 12 months. Work 
performance was worse in the leaflet group than the physiother-
apist- led exercise group at 6 months but there were no significant 
differences in days taken off work or presenteeism. Compared 
with the leaflet group, those in the physiotherapist- led exercise 
group perceived that shoulder pain would continue for a shorter 
duration (timeline) at 6 weeks, had less effect emotionally 
(emotional representation) at 6 months and on their life (conse-
quences) at 12 months, can be helped by treatments to a greater 
extent (treatment control) at 12 months, and had greater control 
over shoulder pain (personal control) at 12 months. Those in the 
ultrasound- guided injection group perceived that their shoulder 
pain had less effect emotionally (emotional representation) at 
6 weeks and reported lower work presenteeism at 12 months 
(table 2) than those in the unguided injection group. There were 
no other significant differences in secondary outcomes between 
the exercise or injection groups.
Exercise adherence, defined as performing exercises at least 
once daily, was more common in the physiotherapist- led exer-
cise group than the leaflet group at 6 weeks (85.6% vs 64.1%) 
and 6 months (63.2% vs 50.8%) but not at 12 months (48.9% 
vs 53.2%) (table 3). There were no differences in the propor-
tion undertaking exercise for longer than 10 min at any time 
point. Exercise adherence, frequency or duration did not differ 
between the injection groups. Confidence in and satisfaction with 
treatment was greater with ultrasound- guided than unguided 
injection, particularly at 6- week follow- up, and with physiother-
apist- led exercise than the leaflet at all time points. The cumula-
tive number of participants who underwent repeat injection was 
4 by 6 weeks, 34 by 6 months and 45 by 12 months. This did not 
differ between treatment groups at any time point.
There was no significant interaction effect of combining 
US- guided injection and physiotherapist- led exercise (interaction 
coefficient: 6 weeks 4.63 (95% CI −5.91 to 15.17, p=0.389); 
6 months 6.65 (−5.01 to 18.32, p=0.264); 12 months 12.76 
(−1.56 to 27.07, p=0.081).
Three participants in the unguided injection group did not 
receive an injection and one in the ultrasound- guided group 
received an unguided injection. For the injection comparison, the 
findings of the per- protocol analysis did not differ from the ITT 
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analysis. Of 128 participants randomised to receive physiother-
apist- led exercise, 12 (9%) attended no physiotherapy appoint-
ments, 42 (33%) attended 1–5 sessions, 71 (56%) 6–8 sessions 
as per protocol and 3 (2%) 9–10 sessions (median 6; IQR 3–7). 
Thirteen (10%) participants in the leaflet group reported seeing 
a physiotherapist about shoulder pain at least once during the 
follow- up. The mean between- group per- protocol differences 
in total SPADI (95% CI)) for the exercise interventions were: 
6 weeks −1.55 (−6.57 to 3.48), 6 months −6.91 (−13.08 to 
–0.74) and 12 months −6.66 (−14.24 to 0.92). The CACE 
results for the primary endpoints were: 6 weeks mean difference 
(95% CI) for US- guided versus unguided injection −3.45 (−9.51 
to 2.61); 6 months for exercise versus no exercise −11.2 (−19.6 
to –2.76).
There was one serious adverse event. A participant randomised 
to receive ultrasound- guided injection and physiotherapist- led 
exercise was hospitalised with pyelonephritis. Shoulder pain 
was temporarily more severe following injection in 49 (48%) 
participants in the ultrasound- guided group and 51 (49%) in the 
unguided group. Of these, this lasted longer than 3 days in 17 
(35%) and 20 (39%) participants, respectively. Minor adverse 
events such as discomfort during the injection or local skin 
changes, presyncope, nausea or flushing following the injec-
tion were uncommon (ultrasound- guided injection 16 (13%), 
Table 1 Baseline characteristics of participants (n=256) by treatment groups
Key characteristics
Overall
US- guided injection 
plus physiotherapist- led 
exercise
US- guided 
injection plus 
leaflet
Unguided injection plus 
physiotherapist- led 
exercise
Unguided 
injection 
plus leaflet
n=256 n=64 n=64 n=64 n=64
Non- clinical characteristics
Age, mean (SD) 53.8 (10.2) 55.6 (10.5) 54.8 (10.0) 51.9 (10.7) 53.0 (9.5)
Females, n (%) 133 (52.0) 37 (57.8) 29 (45.3) 45 (70.3) 22 (34.4)
Previous or current smokers, n (%) 139 (54.3) 29 (45.3) 38 (59.4) 36 (56.3) 36 (56.3)
Right handed, n (%) 217 (84.8) 59 (92.2) 52 (81.3) 51 (79.7) 55 (85.9)
Currently in paid job, n (%) 141 (55.1) 31 (48.4) 35 (54.5) 34 (53.1) 41 (64.1)
Time off work in past 12 months because of shoulder 
problem, n (%)
44 (29.3) 10 (28.6) 13 (36.1) 8 (22.9) 13 (29.6)
Shoulder pain interference with work (NRS scale; 0–10) mean 
(SD)
4.8 (2.9) 4.6 (3.0) 5.2 (2.8) 4.2 (3.0) 4.9 (2.9)
Live alone, n (%) 39 (15.4) 10 (15.9) 12 (18.8) 7 (11.1) 10 (15.9)
Clinical characteristics
SPADI,* mean (SD)
  Pain subscale score 70.6 (15.5) 69.1 (17.3) 72.9 (14.8) 70.9 (15.6) 69.4 (15.5)
  Disability subscale score 55.1 (21.5) 54.3 (22.4) 57.3 (21.1) 57.1 (19.3) 51.6 (22.9)
  Total SPADI score 61.1 (18.1) 60.0 (19.2) 63.4 (17.6) 62.4 (16.5) 58.4 (18.9)
Pain severity today (NRS scale; 0–10), mean (SD) 5.7 (2.0) 5.6 (2.1) 5.9 (2.0) 5.4 (1.9) 5.8 (2.0)
Both shoulders affected, n (%) 20 (7.8) 7 (10.9) 3 (4.7) 5 (7.8) 5 (7.8)
Duration of shoulder pain, n (%)
  <3 months 28 (10.9) 6 (9.4) 5 (7.8) 8 (12.5) 9 (14.0)
  3–6 months 50 (19.5) 16 (25.0) 13 (20.3) 9 (14.0) 12 (18.8)
  6–12 months 74 (28.9) 17 (26.6) 18 (28.1) 26 (40.6) 13 (20.3)
  >12 months 104 (40.6) 25 (39.1) 28 (43.8) 21 (32.8) 30 (46.9)
Previous episode of shoulder pain, n (%) 87 (34.0) 16 (25.0) 24 (37.5) 17 (26.6) 30 (46.9)
Troubled by shoulder pain in bed most or every night, n (%) 205 (80.1) 48 (75.0) 51 (79.7) 51 (79.7) 55 (85.9)
Pain self- efficacy scale,† mean (SD) 35.6 (15.3) 35.2 (15.3) 35.4 (13.7) 34.9 (14.0) 36.7 (10.8)
Fear of movement,‡ mean (SD) 27.0 (5.1) 28.0 (5.4) 27.2 (4.8) 26.4 (4.6) 26.4 (5.4)
SF-12- PCS§, mean (SD) 38.1 (9.7) 37.3 (8.9) 38.5 (9.5) 38.1 (10.9) 38.5 (9.8)
SF-12- MCS¶, mean (SD) 47.2 (12.6) 47.9 (12.7) 46.8 (13.3) 45.8 (12.4) 48.1 (12.2)
Other health conditions,** n (%) 137 (53.5) 38 (59.4) 32 (50.0) 37 (57.8) 30 (46.9)
Widespread pain, n (%) 62 (24.8) 15 (23.8) 19 (30.7) 17 (26.6) 11 (18.0)
BMI categories, n (%)
  Normal/underweight 74 (29.5) 17 (26.6) 17 (26.6) 22 (36.1) 18 (29.0)
  Overweight 62 (24.7) 22 (34.4) 13 (20.3) 12 (19.7) 15 (24.2)
  Obese/morbidly obese 115 (45.8) 25 (39.1) 34 (53.1) 27 (44.3) 29 (46.8)
*Shoulder Pain and Disability Index=Primary outcome measure (each scale/subscale ranges from 0 to 100; 0=no pain/difficulty, 100=worst pain/so difficult it required help).
†10 item scale, score range=0–60 (0=not at all confident, 60=completely confident).
‡Assessed using Tampa scale for kinesiophobia-11– score range from 11 to 44 with higher scores reflecting greater fear of movement or (re)injury.
§SF PCS.
¶SF MCS (scales based on ‘Normalised’ general population average of 50 with SD 10).
**Health conditions include chest problems, heart problems, deafness, problems with eyesight (excluding need for glasses), raised blood pressure, diabetes, stroke, cancer, liver 
disease, kidney disease and circulation problems in the legs.
BMI, body mass index; MCS, Mental Component Scale; NRS, Numeric Rating Scale; PCS, Physical Component Scale; SF-12, Short Form-12; SPADI, Shoulder Pain and Disability 
Index; US, ultrasound.
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unguided injection 17 (13%)). Exacerbation of shoulder pain 
after performing the exercises was reported by 59 (60%) partic-
ipants who received physiotherapist- led exercise and 60 (59%) 
who received the leaflet. This improved within a couple of hours 
in 22 (37%) and 21 (36%), respectively.
DISCUSSION
Summary of findings
This is the largest trial of exercise and injection interventions to 
treat SAPS. Physiotherapist- led, individualised, supervised and 
progressed exercise produced greater improvements in pain and 
function than providing a standard advice and exercise leaflet. 
The between- group difference at 6 months was no longer signif-
icant by 12 months when exercise adherence had reduced. Ultra-
sound guidance provided no additional benefit over unguided 
injection other than perceived emotional effect of shoulder pain 
at 6 weeks and lower work presenteeism at 12 months.
Interpretation: What this study adds for clinicians who treat 
shoulder pain
We provide further evidence of medium- term beneficial effects 
of physiotherapist- led exercise for SAPS adding to previous 
trials reporting short- term improvements.6 While the optimal 
content and duration of exercise remain uncertain,7 11 we 
demonstrate that an individualised, supervised and progressed 
exercise programme focusing on scapular stability, range of 
motion and rotator cuff strengthening, is clinically effective. 
Potential explanations for its effectiveness include the key char-
acteristics of the programme (individualisation, supervision and 
progression of exercises by physiotherapists over several sessions 
coupled with an individualised and progressed home exercise 
programme); the focus on shoulder stability, movement control 
and rotator cuff strength; high exercise adherence rates; and/
or the contact and attention of the physiotherapist over several 
face- to- face treatment sessions.25 For example, in the physio-
therapy- led exercise group, the mean number of physiothera-
pist sessions attended was six, with 86% reporting performing 
exercises at least once daily at 6 weeks compared with 64% 
in the leaflet group. Only 56% of participants received 6–8 
sessions as per protocol, yet our results highlight the benefits 
of physiotherapist- led exercise for SAPS. Few randomised trials 
have compared physiotherapist- led exercise with self- exercise, 
finding no difference between treatments, although the trials 
are small and follow- up short.7
Baseline SPADI scores were higher (meaning that patients 
had more severe pain/disability) than in several other trials in 
SAPS,36–38 most of which were undertaken in community popu-
lations. Our participants were referred to an NHS musculoskel-
etal service, which may have followed non- response to primary 
care management. Subsequent improvements could reflect 
regression to the mean, Hawthorne effect or placebo effect, 
although adjustment for baseline SPADI score and other covari-
ates should minimise between- group biases. The difference in 
the total SPADI score between exercise groups at 6 months was 
at the lower range of its minimal important change (MIC) of 
8–13 points (mean difference 8.2, effect size 0.45).34 35 While a 
between- group MIC for the SPADI is not known, the between- 
group difference is consistent with previous trials.36–38
Figure 2 Linear mixed- model derivation of unadjusted and adjusted mean differences with 95% CI for SPADI total score at three follow- up time 
points for: (A) injection comparison and (B) exercise comparison. The adjusted model was corrected for baseline SPADI scores, age, sex, shoulder 
problem duration and clinic location. The interaction between the interventions was investigated but was not significant at all time points and hence 
not presented in the table. The bars in the figure represent the CIs for the adjusted mean, not the differences. SPADI, Shoulder Pain and Disability 
Index.
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Original research
The marginal differences seen between injection groups 
contrasts with a 2013 systematic review which reported greater 
improvements in pain with ultrasound- guided injection compared 
with unguided injection in people with shoulder pathology.17 In 
studies included in this review, between- group differences were 
modest, sample sizes were small, follow- up was short and/or the 
eligibility criteria for inclusion into the study (and thus corti-
costeroid injection) were heterogeneous. The clinicians who 
undertook the injections in our study undertook trial- specific 
training, demonstrated clinical competency, and had extensive 
clinical experience or had completed accredited training.22 We 
have previously reported that the majority of ultrasound- guided 
injections in the trial were placed accurately, demonstrating 
optimal delivery of the intervention.39 However, a previous trial 
found no difference in shoulder pain and function between a 
systemic intramuscular (gluteal) corticosteroid injection and 
ultrasound- guided subacromial injection in patients with rotator 
cuff disease,40 suggesting that accurate placement of corticoste-
roid injection in the subacromial bursa may be less important 
than previously suggested.
Strengths and limitations
Strengths of our trial include the factorial design that allowed 
us to address two primary research questions, the sample size, 
length of follow- up and intervention training and protocols. A 
limitation relevant to both the exercise and injection intervention 
is the single- blinded design, common in non- pharmacological 
intervention trials, although sham ultrasound guidance could 
have facilitated double blinding of the injection interventions. 
However, not blinding for ultrasound guidance would make it 
more likely to find a difference favouring ultrasound- guided 
injection, in contrast to our findings. There was no interaction 
effect between ultrasound- guided injection and physiothera-
pist- led exercise although this secondary objective was under-
powered and 95% CIs wide.
Our trial registration and published protocol stated we would 
recruit patients with subacromial impingement syndrome 
(SIS),22 consistent with terminology in use at that time. Here, we 
adopt the term SAPS, recognising that this or rotator cuff- related 
shoulder pain is now preferred to SIS.41 42 SAPS was diagnosed 
clinically, rather than requiring imaging, which reflects routine 
clinical practice and increases the generalisability of our find-
ings, although the clinical tests employed lack sensitivity and 
specificity.43 44 Eligibility criteria included the Hawkins- Kennedy 
test and pain on abduction which are currently recommended 
to confirm SAPS,42 although others have recently proposed 
that it is feasible to conduct a clinical assessment of shoulder 
pain without including such special clinical tests as they cannot 
localise the anatomical structure(s) causing symptoms and should 
be considered as pain- provocation tests only.45 We assessed only 
self- reported outcomes but not the effect of exercise on shoulder 
strength, scapular stability or movement, nor can we determine 
which aspects of the physiotherapist- led exercise programme 
contributed most to the benefit observed.
Conclusion
Physiotherapist- led exercise was more effective than an advice 
and exercise leaflet for patients with SAPS. We provide evidence 
for policy- makers, payers and services that outcomes are opti-
mised by supervising, individualising and progressing exercise 
delivery by physiotherapists rather than offering standard exer-
cise advice to all patients. We found no benefit from augmenting 
injection with ultrasound- guidance, meaning that patients can be 
offered injection without requiring specialist skills, training and 
equipment necessary for ultrasound- guided injection.
Key messages
What are the findings?
 ► Our trial is the largest of exercise and injection interventions 
for subacromial pain syndrome.
 ► Physiotherapist- led, individualised, supervised and progressed 
exercise provides greater improvements in pain and function 
than providing an exercise leaflet, whereas ultrasound- guided 
subacromial corticosteroid injection provides no additional 
clinical benefit over unguided injection.
How might it impact on clinical practice in the future?
 ► Patients should have access to physiotherapist- led exercise 
programmes rather than offering the same standard advice 
and exercise information to all patients.
 ► Subacromial corticosteroid injections can be performed 
unguided without guidance from ultrasound.
Acknowledgements This project was undertaken with the support of Keele 
Clinical Trials Unit, Keele University, UK. The authors would like to thank Kris 
Clarkson, Treena Larkin, and Sue Weir. We would also like to thank the clinicians, 
managerial and administrative staff of the Midlands Partnership NHS Foundation 
Trust, and members of the trial steering committee and data monitoring committee.
Contributors All authors contributed to trial design, interpretation of data and 
critical revision of the report; approved the final version of the report; and agree to 
be accountable for all aspects of the work. ER, EH, SJa, KS, DvdW and NEF conceived 
the trial. ER, IZ, KS and JY contributed to acquisition of data. ROO and ML performed 
the statistical analysis. ER wrote the first draft of the report with input from RO and 
NEF. NEF and ML had full access to all the data in the study and take responsibility 
for the integrity of the data and the accuracy of the data analysis.
Funding This paper presents independent research funded by the Arthritis Research 
UK Primary Care Centre grant (Grant Number 18139) and by the National Institute 
for Health; Research (NIHR) under its Research for Patient Benefit programme 
(grant reference number PB- PG-1207–15064). NEF and EH are both NIHR Senior 
Investigators. NEF was supported through an NIHR Research Professorship (NIHR- 
RP- 011–015).
Disclaimer The views expressed are those of the authors and not necessarily those 
of the NHS, the NIHR or the Department of Health and Social Care.
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting, or dissemination plans of this research. Refer to the 
Methods section for further details.
Patient consent for publication Not required.
Ethics approval The trial was approved by the Black Country Research Ethics 
Committee, England (10/H1202/72).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. Data 
can be accessed via the Keele data repository athttps://www. keele. ac. uk/ pcsc/ 
research/ ctu/.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Edward Roddy http:// orcid. org/ 0000- 0002- 8954- 7082
Danielle A van der Windt http:// orcid. org/ 0000- 0002- 7248- 6703
REFERENCES
 1 Luime JJ, Koes BW, Hendriksen IJM, et al. Prevalence and incidence of shoulder pain in 
the general population; a systematic review. Scand J Rheumatol 2004;33:73–81.
 2 van der Windt DA, Koes BW, de Jong BA, et al. Shoulder disorders in general practice: 
incidence, patient characteristics, and management. Ann Rheum Dis 1995;54:959–64.
 o
n
 Septem
ber 1, 2020 by guest. Protected by copyright.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2019-101268 on 19 August 2020. Downloaded from 
11Roddy E, et al. Br J Sports Med 2020;0:1–11. doi:10.1136/bjsports-2019-101268
Original research
 3 Hanchard N, Cummins J, Jeffries J. Evidence- Based clinical guidelines for the diagnosis, 
assessment and physiotherapy management of shoulder impingement syndrome. 
London: Chartered Society of Physiotherapy, 2004.
 4 Kulkarni R, Gibson J, Brownson P, et al. Subacromial shoulder pain. Shoulder Elbow 
2015;7:135–43.
 5 Michener LA, Walsworth MK, Burnet EN. Effectiveness of rehabilitation for patients 
with subacromial impingement syndrome: a systematic review. J Hand Ther 
2004;17:152–64.
 6 Abdulla SY, Southerst D, Côté P, et al. Is exercise effective for the management of 
subacromial impingement syndrome and other soft tissue injuries of the shoulder? 
A systematic review by the Ontario protocol for traffic injury management (optima) 
collaboration. Man Ther 2015;20:646–56.
 7 Gebremariam L, Hay EM, van der Sande R, et al. Subacromial impingement 
syndrome--effectiveness of physiotherapy and manual therapy. Br J Sports Med 
2014;48:1202–8.
 8 Haik MN, Alburquerque- Sendín F, Moreira RFC, et al. Effectiveness of physical therapy 
treatment of clearly defined subacromial pain: a systematic review of randomised 
controlled trials. Br J Sports Med 2016;50:1124–34.
 9 Shire AR, Stæhr TAB, Overby JB, et al. Specific or General exercise strategy for 
subacromial impingement syndrome- does it matter? A systematic literature review 
and meta analysis. BMC Musculoskelet Disord 2017;18:158.
 10 Klintberg IH, Cools AMJ, Holmgren TM, et al. Consensus for physiotherapy for 
shoulder pain. Int Orthop 2015;39:715–20.
 11 Littlewood C, Malliaras P, Chance- Larsen K. Therapeutic exercise for rotator cuff 
tendinopathy: a systematic review of contextual factors and prescription parameters. 
Int J Rehabil Res 2015;38:95–106.
 12 Pieters L, Lewis J, Kuppens K, et al. An update of systematic reviews examining the 
effectiveness of conservative physical therapy interventions for subacromial shoulder 
pain. J Orthop Sports Phys Ther 2020;50:131–41.
 13 Steuri R, Sattelmayer M, Elsig S, et al. Effectiveness of conservative interventions 
including exercise, manual therapy and medical management in adults with shoulder 
impingement: a systematic review and meta- analysis of RCTs. Br J Sports Med 
2017;51:1340–7.
 14 Dong W, Goost H, Lin X- B, et al. Treatments for shoulder impingement syndrome: a 
PRISMA systematic review and network meta- analysis. Medicine 2015;94:e510.
 15 Rhon DI, Boyles RB, Cleland JA. One- Year outcome of subacromial corticosteroid 
injection compared with manual physical therapy for the management of the 
unilateral shoulder impingement syndrome: a pragmatic randomized trial. Ann Intern 
Med 2014;161:161–9.
 16 Esenyel CZ, Esenyel M, Yeşiltepe R, et al. [The correlation between the accuracy 
of steroid injections and subsequent shoulder pain and function in subacromial 
impingement syndrome]. Acta Orthop Traumatol Turc 2003;37:41–5. Turkish.
 17 Sage W, Pickup L, Smith TO, et al. The clinical and functional outcomes of ultrasound- 
guided vs landmark- guided injections for adults with shoulder pathology--a 
systematic review and meta- analysis. Rheumatology 2013;52:743–51.
 18 Saeed A, Khan M, Morrissey S, et al. Impact of outpatient clinic ultrasound imaging 
in the diagnosis and treatment for shoulder impingement: a randomized prospective 
study. Rheumatol Int 2014;34:503–9.
 19 Cole BF, Peters KS, Hackett L, et al. Ultrasound- Guided versus blind subacromial 
corticosteroid injections for subacromial impingement syndrome: a randomized, 
double- blind clinical trial. Am J Sports Med 2016;44:702–7.
 20 Bhayana H, Mishra P, Tandon A, et al. Ultrasound guided versus landmark guided 
corticosteroid injection in patients with rotator cuff syndrome: randomised controlled 
trial. J Clin Orthop Trauma 2018;9:S80–5.
 21 Akbari N, Ozen S, Şenlikçi HB, et al. Ultrasound- Guided versus blind subacromial 
corticosteroid and local anesthetic injection in the treatment of subacromial 
impingement syndrome: a randomized study of efficacy. Jt Dis Relat Surg 
2020;31:115–22.
 22 Roddy E, Zwierska I, Hay EM, et al. Subacromial impingement syndrome and pain: 
protocol for a randomised controlled trial of exercise and corticosteroid injection (the 
support trial). BMC Musculoskelet Disord 2014;15:81.
 23 Bigliani LU, Levine WN. Subacromial impingement syndrome. J Bone Joint Surg Am 
1997;79:1854–68.
 24 Physio tools. Saunders exercises: exercise software upper quadrant dynamic stability. 
Available: www. physiotools. com
 25 Stevenson K, Jackson S, Shufflebotham J, et al. Development and delivery of 
a physiotherapist- led exercise intervention in a randomised controlled trial 
for subacromial impingement syndrome (the support trial). Physiotherapy 
2017;103:379–86.
 26 Roach KE, Budiman- Mak E, Songsiridej N, et al. Development of a shoulder pain and 
disability index. Arthritis Care Res 1991;4:143–9. 4:143â€“149.
 27 Dawson J, Fitzpatrick R, Carr A. Questionnaire on the perceptions of patients about 
shoulder surgery. J Bone Joint Surg Br 1996;78:593:600. ;78:593â€“600.
 28 van der Windt DA, Koes BW, Devillé W, et al. Effectiveness of corticosteroid injections 
versus physiotherapy for treatment of painful stiff shoulder in primary care: 
randomised trial. BMJ 1998;317:1292–6.
 29 Brazier JE, Roberts J. The estimation of a preference- based measure of health from the 
SF-12. Med Care 2004;42:851–9.
 30 Nicholas MK. The pain self- efficacy questionnaire: taking pain into account. Eur J Pain 
2007;11:153–63.
 31 Woby SR, Roach NK, Urmston M, et al. Psychometric properties of the TSK-11: a 
shortened version of the Tampa scale for Kinesiophobia. Pain 2005;117:137–44.
 32 Koopman C, Pelletier KR, Murray JF, et al. Stanford presenteeism scale: health status 
and employee productivity. J Occup Environ Med 2002;44:14–20.
 33 Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J 
Psychosom Res 2006;60:631–7.
 34 Roy J- S, MacDermid JC, Woodhouse LJ. Measuring shoulder function: a systematic 
review of four questionnaires. Arthritis Rheum 2009;61:623–32.
 35 Tveitå EK, Ekeberg OM, Juel NG, et al. Responsiveness of the shoulder pain and 
disability index in patients with adhesive capsulitis. BMC Musculoskelet Disord 
2008;9:161.
 36 Crawshaw DP, Helliwell PS, Hensor EMA, et al. Exercise therapy after corticosteroid 
injection for moderate to severe shoulder pain: large pragmatic randomised trial. BMJ 
2010;340:c3037.
 37 Engebretsen K, Grotle M, Bautz- Holter E, et al. Radial extracorporeal shockwave 
treatment compared with supervised exercises in patients with subacromial pain 
syndrome: single blind randomised study. BMJ 2009;339:b3360.
 38 Bennell K, Wee E, Coburn S, et al. Efficacy of standardised manual therapy and home 
exercise programme for chronic rotator cuff disease: randomised placebo controlled 
trial. BMJ 2010;340:c2756.
 39 Raval P, Ogollah R, Hall A, et al. Does accuracy of ultrasound- guided corticosteroid 
injection predict outcome in pain and function in subacromial impingement 
syndrome ultrasound 2015. 47th annual scientific meeting of the British medical 
ultrasound Society final programme. Available: https://www. bmus. org/ static/ uploads/ 
resources/ BMUS_ Scientific_ Programme_ 2015_ FINAL. pdf [Accessed 3rd October 
2019].
 40 Ekeberg OM, Bautz- Holter E, Tveitå EK, et al. Subacromial ultrasound guided or 
systemic steroid injection for rotator cuff disease: randomised double blind study. BMJ 
2009;338:a3112.
 41 Lewis J. Rotator cuff related shoulder pain: assessment, management and 
uncertainties. Man Ther 2016;23:57–68.
 42 Diercks R, Bron C, Dorrestijn O, et al. Guideline for diagnosis and treatment of 
subacromial pain syndrome: a multidisciplinary review by the Dutch orthopaedic 
association. Acta Orthop 2014;85:314–22.
 43 Hegedus EJ, Goode A, Campbell S, et al. Physical examination tests of the shoulder: 
a systematic review with meta- analysis of individual tests. Br J Sports Med 
2008;42:80–92.
 44 Hegedus EJ, Goode AP, Cook CE, et al. Which physical examination tests provide 
clinicians with the most value when examining the shoulder? update of a systematic 
review with meta- analysis of individual tests. Br J Sports Med 2012;46:964–78.
 45 Salamh P, Lewis J. It is time to put special tests for rotator Cuff- Related shoulder pain 
out to pasture. J Orthop Sports Phys Ther 2020;50:222–5.
 o
n
 Septem
ber 1, 2020 by guest. Protected by copyright.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2019-101268 on 19 August 2020. Downloaded from 
